Stay updated on Pembrolizumab Combo in Resectable NSCLC Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab Combo in Resectable NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab Combo in Resectable NSCLC Clinical Trial page

  1. Check
    5 days ago
    Change Detected
    Summary
    City location text for Bucharest, Romania changed from the Romanian spelling (“București”) to the English spelling (“Bucharest”) while keeping the same address entry.
    Difference
    0.0%
    Check dated 2026-04-23T13:59:05.000Z thumbnail image
  2. Check
    12 days ago
    Change Detected
    Summary
    Revision label updated from v3.5.0 to v3.5.2. No study content or features were changed.
    Difference
    0.0%
    Check dated 2026-04-16T09:55:30.000Z thumbnail image
  3. Check
    19 days ago
    No Change Detected
  4. Check
    26 days ago
    Change Detected
    Summary
    Publication added under Publications: A Subgroup Analysis of Perioperative Pembrolizumab in Clinical Stage II NSCLC from KEYNOTE-671. Eur J Cardiothorac Surg. 2026 Mar 10; 68(3): ezag028.
    Difference
    0.0%
    Check dated 2026-04-02T00:13:38.000Z thumbnail image
  5. Check
    33 days ago
    Change Detected
    Summary
    Added Naples, Campania, Italy, 80131 and removed Napoli, Campania, Italy, 80131 from the locations list.
    Difference
    0.0%
    Check dated 2026-03-25T20:35:22.000Z thumbnail image
  6. Check
    40 days ago
    Change Detected
    Summary
    The page now shows Revision: v3.5.0 at the top, replacing Revision: v3.4.3.
    Difference
    0.0%
    Check dated 2026-03-18T16:45:39.000Z thumbnail image
  7. Check
    48 days ago
    Change Detected
    Summary
    Revision: v3.4.3 updated from v3.4.2.
    Difference
    0.0%
    Check dated 2026-03-11T11:21:51.000Z thumbnail image

Stay in the know with updates to Pembrolizumab Combo in Resectable NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Combo in Resectable NSCLC Clinical Trial page.